We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 12, 2020

Osimertinib vs Platinum–Pemetrexed in EGFR T790M Advanced NSCLC With Progression

Annals of Oncology


Additional Info

Annals of Oncology
Osimertinib Versus Platinum-Pemetrexed for Patients With EGFR T790M Advanced NSCLC and Progression on a Prior EGFR-Tyrosine Kinase Inhibitor: AURA3 Overall Survival Analysis
Ann. Oncol 2020 Aug 27;[EPub Ahead of Print], VA Papadimitrakopoulou, TS Mok, J-Y Han, M-J Ahn, A Delmonte, SS Ramalingam, SW Kim, FA Shepherd, J Laskin, Y He, H Akamatsu, WSME Theelen, W-C Su, T John, M Sebastian, H Mann, M Miranda, G Laus, Y Rukazenkov, Y-L Wu

Further Reading